MARKET

ARMP

ARMP

Armata Pharmaceuticals Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

3.635
+0.015
+0.41%
Closed 16:00 09/24 EDT
OPEN
3.630
PREV CLOSE
3.620
HIGH
3.650
LOW
3.620
VOLUME
5.90K
TURNOVER
--
52 WEEK HIGH
10.48
52 WEEK LOW
2.560
MARKET CAP
90.65M
P/E (TTM)
-3.0505
1D
5D
1M
3M
1Y
5Y
Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today anno...
PR Newswire - PRF · 09/08 12:01
Armata Pharmaceuticals Q2 EPS $(0.25) Up From $(0.26) YoY
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.25) per share. This is a 3.85 percent increase over losses of $(0.26) per share from the same period last year.
Benzinga · 08/12 20:52
Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/12 08:58
Will Armata Pharmaceuticals, Inc. (ARMP) Report Negative Q2 Earnings? What You Should Know
Zacks.com · 08/05 19:00
Armata Pharma CEO steps down
Armata Pharmaceuticals (NYSE:ARMP) announces that its current CEO, Todd R. Patrick, is retiring from day-to-day active management of the Company, effective today. The Company's current President and Chief Development Officer,
Seekingalpha · 08/02 12:11
Armata Pharmaceuticals Says CEO Retiring; Successor Named
MT Newswires · 08/02 10:07
Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference
/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today anno...
PR Newswire - PRF · 07/07 11:30
Arm has co-founded a ‘deep tech’ start-up accelerator in Cambridge
Arm has co-founded a new start-up accelerator in Cambridge, England, to try and help young "deep tech" firms to grow into the next generation of tech giants.
CNBC.com · 06/11 12:51
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARMP. Analyze the recent business situations of Armata Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARMP stock price target is 7.67 with a high estimate of 9.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 13
Institutional Holdings: 119.54K
% Owned: 0.48%
Shares Outstanding: 24.94M
TypeInstitutionsShares
Increased
4
43.82K
New
0
0
Decreased
5
147.23K
Sold Out
13
36.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chief Executive Officer/Director
Brian Varnum
Chief Financial Officer
Steven Martin
Vice President - Operations
Duane Morris
Vice President
Mina Pastagia
Director
Todd Patrick
Independent Director
Jules Haimovitz
Independent Director
Odysseas Kostas
Independent Director
Robin Kramer
Independent Director
Joseph Patti
Independent Director
Todd Peterson
Independent Director
Sarah Schlesinger
No Data
About ARMP
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using bacteriophage-based technology. The Company is a developer of synthetic phage platform, which targets therapeutics for the treatment of various multidrug-resistant bacterial infections. It develops synthetic phage products that target a specific pathogen begins with the isolation of natural phages from environmental and clinical samples. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AP-PA02 and AP-SA02.

Webull offers kinds of Armata Pharmaceuticals Inc stock information, including AMEX:ARMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARMP stock methods without spending real money on the virtual paper trading platform.